Japanese IT Stock News

TSE:1720
TSE:1720Construction

Assessing Tokyu Construction (TSE:1720) Valuation After Strong Nine Month Earnings And Governance Changes

Earnings and governance changes put Tokyu Construction in focus Tokyu Construction (TSE:1720) has drawn fresh attention after reporting nine month revenue of ¥239,560 million and net income of ¥7,969 million, alongside a board meeting considering leadership changes and a shift to an Audit and Supervisory Committee structure. See our latest analysis for Tokyu Construction. The earnings and governance announcements sit alongside strong recent market performance, with a 7 day share price return...
TSE:8136
TSE:8136Specialty Retail

Sanrio Company (TSE:8136) Valuation After Upgraded Earnings And Dividend Guidance

Sanrio Company (TSE:8136) has put investors on alert after a February 12 board meeting combined three shareholder focused moves: an upcoming stock split, higher full year earnings guidance, and an increased dividend forecast. See our latest analysis for Sanrio Company. Despite Sanrio’s stronger guidance and dividend outlook, the share price is currently ¥4,764, with a 3 month share price return of an 18% decline and a 1 year total shareholder return of a 22% decline, while the 5 year total...
TSE:4204
TSE:4204Industrials

Is Sekisui Chemical’s Completed ¥26.4b Buyback Altering The Investment Case For Sekisui Chemical (TSE:4204)?

Sekisui Chemical has now completed its previously announced share repurchase plan, buying back 10,000,000 shares (2.43% of shares) for ¥26,420.48 million by February 9, 2026. This completed buyback reduces the share count and may enhance per-share metrics, underlining management’s willingness to return capital to investors. Next, we’ll examine how the completion of this sizeable buyback program may influence Sekisui Chemical’s existing investment narrative. We've uncovered the 14 dividend...
TSE:4502
TSE:4502Pharmaceuticals

Takeda Pharmaceutical’s Valuation After FDA Priority Review And New AI Drug Discovery Collaboration

Takeda Pharmaceutical (TSE:4502) just cleared two meaningful milestones, with the U.S. FDA granting Priority Review for its narcolepsy type 1 candidate oveporexton and a new AI-focused drug discovery collaboration with Iambic. See our latest analysis for Takeda Pharmaceutical. The recent regulatory progress for oveporexton and the AI drug discovery partnership with Iambic come as Takeda’s shares trade at ¥5,609, with a 30-day share price return of 11.73%, a 90-day share price return of...
TSE:8987
TSE:8987Office REITs

A Look At Japan Excellent (TSE:8987) Valuation After New ¥100,000 Million Bond Shelf Registration

Japan Excellent (TSE:8987) has filed a shelf registration for up to ¥100,000 million in investment corporation bonds, giving it a multi-year funding option for property acquisitions, upkeep, refinancing, and day-to-day operations. See our latest analysis for Japan Excellent. That funding option lands at a time when the share price is around ¥151,000, with a modest 90 day share price return of 1.68% and a much stronger 1 year total shareholder return of 27.43%. This points to momentum that has...
TSE:7180
TSE:7180Banks

Assessing Kyushu Financial Group (TSE:7180) Valuation After Strong Profit Growth, Dividend Increases And Ongoing Buybacks

Kyushu Financial Group (TSE:7180) has just paired double-digit income growth and roughly 48% profit growth with expanding assets and equity, while reaffirming its dividend policy, higher total dividends, and continued share buybacks. See our latest analysis for Kyushu Financial Group. Those results and the January buybacks have arrived alongside strong price momentum, with a 30 day share price return of 25.82% and a 90 day gain of 56.48%. The 1 year total shareholder return of 104.23% points...
TSE:9434
TSE:9434Wireless Telecom

SoftBank’s Earnings per Share Gains Might Change The Case For Investing In SoftBank (TSE:9434)

SoftBank Corp. has reported past earnings for the nine months ended December 31, 2025, with sales of ¥5.20 trillion and net income of ¥485.52 billion, both higher than the previous year. The improvement in basic and diluted earnings per share from continuing operations suggests greater profit generation per share, which may influence how investors assess SoftBank’s earnings power. We’ll now examine how this growth in sales and net income shapes SoftBank’s broader investment narrative and...